Contemporary medical management of peripheral arterial disease: A focus on risk reduction and symptom relief for intermittent claudication

Cardiology Clinics

Volumn 33, Issue 1, 2015, Pages 111-137

  Agrawal, Kush ^a   Eberhardt, Robert T ^b  

^a BOSTON MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ankle brachial index; Atherosclerotic risk factors; Cilostazol; Intermittent claudication; Pentoxifylline; Peripheral arterial disease; Supervised exercise therapy

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARNITINE; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NAFTIDROFURYL OXALATE; PENTOXIFYLLINE; PICOTAMIDE; PLACEBO; RAMIPRIL; SIMVASTATIN; TETRAZOLE DERIVATIVE;

AGE DISTRIBUTION; ANKLE BRACHIAL INDEX; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; GENE THERAPY; GLYCEMIC CONTROL; HOME CARE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KINESIOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SMOKING; SMOKING CESSATION; STEM CELL TRANSPLANTATION; TREADMILL EXERCISE; TREATMENT DURATION; TREATMENT INDICATION; INTERMITTENT CLAUDICATION; MULTIMODALITY CANCER THERAPY; PERIPHERAL ARTERIAL DISEASE; SYMPTOM ASSESSMENT;

ANKLE BRACHIAL INDEX; COMBINED MODALITY THERAPY; EXERCISE THERAPY; HUMANS; INTERMITTENT CLAUDICATION; PENTOXIFYLLINE; PERIPHERAL ARTERIAL DISEASE; RISK REDUCTION BEHAVIOR; SYMPTOM ASSESSMENT; TETRAZOLES;

EID: 84923204982     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2014.09.010     Document Type: Review

References (117)

1. Hirsch A.T., Haskal Z.J., Hertzer N.R., et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to develop guidelines for the management of patients with peripheral arterial disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. JAm Coll Cardiol 2006, 47(6):1239-1312.
2. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125(1):e2-e220. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/22179539.
3. Ostchega Y., Paulose-Ram R., Dillon C.F., et al. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. JAm Geriatr Soc 2007, 55(4):583-589.
4. Hirsch A.T., Criqui M.H., Treat-Jacobson D., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001, 286(11):1317-1324.
5. Agnelli G., Cimminiello C., Meneghetti G., et al. Low ankle-brachial index predicts an adverse 1-year outcome after acute coronary and cerebrovascular events. JThromb Haemost 2006, 4(12):2599-2606.
6. Boden W.E., Cherr G.S., Eagle K.A., et al. Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosis. Crit Pathw Cardiol 2010, 9(3):116-125.
7. Allison M.A., Criqui M.H., McClelland R.L., et al. The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). JAm Coll Cardiol 2006, 48(6):1190-1197.
8. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360(9326):7-22. Heart Protection Study Collaborative Group.
9. Fowkes F.G., Housley E., Riemersma R.A., et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 1992, 135(4):331-340.
10. Krupski W.C. The peripheral vascular consequences of smoking. Ann Vasc Surg 1991, 5(3):291-304.
11. Shammas N.W. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag 2007, 3(2):229-234.
12. Bartholomew J.R., Olin J.W. Pathophysiology of peripheral arterial disease and risk factors for its development. Cleve Clin J Med 2006, 73(Suppl 4):S8-S14.
13. He Y., Lam T.H., Jiang B., et al. Passive smoking and risk of peripheral arterial disease and ischemic stroke in Chinese women who never smoked. Circulation 2008, 118(15):1535-1540.
14. Grana R., Benowitz N., Glantz S.A. E-cigarettes: ascientific review. Circulation 2014, 129(19):1972-1986.
15. Selvin E., Marinopoulos S., Berkenblit G., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004, 141(6):421-431.
16. American Diabetes Association Peripheral arterial disease in people with diabetes. Diabetes Care 2003, 26(12):3333-3341.
17. Pedicino D., Giglio A.F., Galiffa V.A., et al. Type 2 diabetes, immunity and cardiovascular risk: A Complex Relationship, Pathophysiology and Complications of Diabetes Mellitus 2012, InTech. O. Oguntibeju (Ed.).
18. Jude E.B., Oyibo S.O., Chalmers N., et al. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 2001, 24(8):1433-1437.
19. Kannel W.B., McGee D.L. Update on some epidemiologic features of intermittent claudication: the Framingham Study. JAm Geriatr Soc 1985, 33(1):13-18.
20. Newman A.B., Siscovick D.S., Manolio T.A., et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 1993, 88(3):837-845.
21. Cardia G., Grisorio D., Impedovo G., et al. Plasma lipids as a risk factor in peripheral vascular disease. Angiology 1990, 41(1):19-22.
22. Murabito J.M., D'Agostino R.B., Silbershatz H., et al. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997, 96(1):44-49.
23. Zhan Y., Yu J., Ding R., et al. Triglyceride to high density lipoprotein cholesterol ratio, total cholesterol to high density lipoprotein cholesterol ratio and low ankle brachial index in an elderly population. Vasa 2014, 43(3):189-197.
24. Ridker P.M., Stampfer M.J., Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001, 285(19):2481-2485.
25. Boushey C.J., Beresford S.A., Omenn G.S., et al. Aquantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995, 274(13):1049-1057.
26. Taylor L.M., Moneta G.L., Sexton G.J., et al. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. JVasc Surg 1999, 29(1):8-19. [discussion: 19-21].
27. Lonn E., Yusuf S., Arnold M.J., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. NEngl J Med 2006, 354(15):1567-1577.
28. Newman A.B., Tyrrell K.S., Kuller L.H. Mortality over four years in SHEP participants with a low ankle-arm index. JAm Geriatr Soc 1997, 45(12):1472-1478.
29. Resnick H.E., Lindsay R.S., McDermott M.M., et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 2004, 109(6):733-739.
30. Heald C.L., Fowkes F.G., Murray G.D., et al. Risk of mortality and cardiovascular disease associated with the ankle-brachial index: systematic review. Atherosclerosis 2006, 189(1):61-69.
31. Fowkes F.G., Murray G.D., Butcher I., et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008, 300(2):197-208.
32. Diehm C., Allenberg J.R., Pittrow D., et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation 2009, 120(21):2053-2061.
33. Criqui M.H., Langer R.D., Fronek A., et al. Mortality over a period of 10 years in patients with peripheral arterial disease. NEngl J Med 1992, 326(6):381-386.
34. Weitz J.I., Byrne J., Clagett G.P., et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996, 94(11):3026-3049.
35. Wennberg P.W. Approach to the patient with peripheral arterial disease. Circulation 2013, 128(20):2241-2250.
36. Rose G.A. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ 1962, 27:645-658.
37. Dormandy J.A., Rutherford R.B. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). JVasc Surg 2000, 31(1 Pt 2):S1-S296.
38. Rooke T.W., Hirsch A.T., Misra S., et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. JVasc Surg 2011, 54(5):e32-e58.
39. Feigelson H.S., Criqui M.H., Fronek A., et al. Screening for peripheral arterial disease: the sensitivity, specificity, and predictive value of noninvasive tests in a defined population. Am J Epidemiol 1994, 140(6):526-534.
40. Beckman J.A., Jaff M.R., Creager M.A. The United States Preventive Services Task Force recommendation statement on screening for peripheral arterial disease: more harm than benefit?. Circulation 2006, 114(8):861-866.
41. Aboyans V., Criqui M.H., Abraham P., et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation 2012, 126(24):2890-2909.
42. McDermott M.M. The magnitude of the problem of peripheral arterial disease: epidemiology and clinical significance. Cleve Clin J Med 2006, 73(Suppl 4):S2-S7.
43. Ramsey D.E., Manke D.A., Sumner D.S. Toe blood pressure. A valuable adjunct to ankle pressure measurement for assessing peripheral arterial disease. JCardiovasc Surg (Torino) 1983, 24(1):43-48.
44. McDermott M.M., Guralnik J.M., Tian L., et al. Associations of borderline and low normal ankle-brachial index values with functional decline at 5-year follow-up: the WALCS (Walking and Leg Circulation Study). JAm Coll Cardiol 2009, 53(12):1056-1062.
45. Rooke T.W., Hirsch A.T., Misra S., et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JAm Coll Cardiol 2013, 61(14):1555-1570.
46. Stone N.J., Robinson J.G., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JAm Coll Cardiol 2014, 63(25 Pt B):2889-2934.
47. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff Aclinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med 2008, 35(2):158-176.
48. Hennrikus D., Joseph A.M., Lando H.A., et al. Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial. JAm Coll Cardiol 2010, 56(25):2105-2112.
49. Silagy C., Lancaster T., Stead L., et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004, (3). CD000146.
50. Odum L.E., O'Dell K.A., Schepers J.S. Electronic cigarettes: do they have a role in smoking cessation?. JPharm Pract 2012, 25(6):611-614.
51. Goniewicz M.L., Kuma T., Gawron M., et al. Nicotine levels in electronic cigarettes. Nicotine Tob Res 2013, 15(1):158-166.
52. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. NEngl J Med 1993, 329(14):977-986.
53. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. NEngl J Med 2008, 358(24):2545-2559.
54. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. NEngl J Med 2008, 359(15):1577-1589.
55. Adler A.I., Stratton I.M., Neil H.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321(7258):412-419.
56. Hoogwerf B.J., Young J.B. The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not. Cleve Clin J Med 2000, 67(4):287-293.
57. Radack K., Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991, 151(9):1769-1776.
58. Paravastu S.C., Mendonca D.A., da Silva A. Beta blockers for peripheral arterial disease. Eur J Vasc Endovasc Surg 2009, 38(1):66-70.
59. Hennekens C.H., Albert C.M., Godfried S.L., et al. Adjunctive drug therapy of acute myocardial infarction-evidence from clinical trials. NEngl J Med 1996, 335(22):1660-1667.
60. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. JVasc Surg 2007, 45(4):645-654. Heart Protection Study Collaborative Group, [discussion: 653-4].
61. Adam D.J., Beard J.D., Cleveland T., et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL): multicentre, randomised controlled trial. Lancet 2005, 366(9501):1925-1934.
62. Sharma S., Thapa R., Jeevanantham V., et al. Comparison of lipid management in patients with coronary versus peripheral arterial disease. Am J Cardiol 2014, 113(8):1320-1325.
63. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285(19):2486-2497.
64. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324(7329):71-86. Antithrombotic Trialists' Collaboration.
65. Berger J.S., Krantz M.J., Kittelson J.M., et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009, 301(18):1909-1919.
66. Fowkes F.G., Price J.F., Stewart M.C., et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010, 303(9):841-848.
67. Bhatt D.L., Fox K.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. NEngl J Med 2006, 354(16):1706-1717.
68. Wong P.F., Chong L.Y., Mikhailidis D.P., et al. Antiplatelet agents for intermittent claudication. Cochrane Database Syst Rev 2011, (11). CD001272.
69. Ota H., Eto M., Kano M.R., et al. Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler Thromb Vasc Biol 2008, 28(9):1634-1639.
70. Elam M.B., Heckman J., Crouse J.R., et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998, 18(12):1942-1947.
71. Pande R.L., Hiatt W.R., Zhang P., et al. Apooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med 2010, 15(3):181-188.
72. Hiatt W.R., Money S.R., Brass E.P. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: a study in long-term effects). JVasc Surg 2008, 47(2):330-336.
73. Beebe H.G., Dawson D.L., Cutler B.S., et al. Anew pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999, 159(17):2041-2050.
74. Chapman T.M., Goa K.L. Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs 2003, 3(2):117-138.
75. Schrör K. The pharmacology of cilostazol. Diabetes Obes Metab 2002, 4(Suppl 2):S14-S19.
76. Drugs for intermittent claudication. Med Lett Drugs Ther 2004, 46(1176):13-15.
77. Aviado D.M., Porter J.M. Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy 1984, 4(6):297-307.
78. Gillings D.B. Pentoxifylline and intermittent claudication: review of clinical trials and cost-effectiveness analyses. JCardiovasc Pharmacol 1995, 25(Suppl 2):S44-S50.
79. Salhiyyah K., Senanayake E., Abdel-Hadi M., et al. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev 2012, (1). CD005262.
80. Wiernsperger N.F. Serotonin, 5-HT2 receptors, and their blockade by naftidrofuryl: a targeted therapy of vascular diseases. JCardiovasc Pharmacol 1994, 23(Suppl 3):S37-S43.
81. Hong H., Mackey W.C. The limits of evidence in drug approval and availability: a case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication. Clin Ther 2014, 36(8):1290-1301.
82. Barradell L.B., Brogden R.N. Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Drugs Aging 1996, 8(4):299-322.
83. Stevens J.W., Simpson E., Harnan S., et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg 2012, 99(12):1630-1638.
84. Shalhoub J., Davies A.H. Adjunctive pharmacotherapies for intermittent claudication-NICE guidance. Heart 2012, 98(3):244-245.
85. Bendermacher B.L., Willigendael E.M., Nicolaï S.P., et al. Supervised exercise therapy for intermittent claudication in a community-based setting is as effective as clinic-based. JVasc Surg 2007, 45(6):1192-1196.
86. Gustafsson T., Kraus W.E. Exercise-induced angiogenesis-related growth and transcription factors in skeletal muscle, and their modification in muscle pathology. Front Biosci 2001, 6:D75-D89.
87. Brendle D.C., Joseph L.J., Corretti M.C., et al. Effects of exercise rehabilitation on endothelial reactivity in older patients with peripheral arterial disease. Am J Cardiol 2001, 87(3):324-329.
88. Hiatt W.R., Regensteiner J.G., Wolfel E.E., et al. Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease. JAppl Physiol (1985) 1996, 81(2):780-788.
89. Tisi P.V., Shearman C.P. The evidence for exercise-induced inflammation in intermittent claudication: should we encourage patients to stop walking?. Eur J Vasc Endovasc Surg 1998, 15(1):7-17.
90. Lane R., Ellis B., Watson L., et al. Exercise for intermittent claudication. Cochrane Database Syst Rev 2014, (7). CD000990.
91. McDermott M.M., Ades P., Guralnik J.M., et al. Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. JAMA 2009, 301(2):165-174.
92. Fokkenrood H.J., Bendermacher B.L., Lauret G.J., et al. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev 2013, (8). CD005263.
93. Makris G.C., Lattimer C.R., Lavida A., et al. Availability of supervised exercise programs and the role of structured home-based exercise in peripheral arterial disease. Eur J Vasc Endovasc Surg 2012, 44(6):569-575. [discussion: 576].
94. Kruidenier L.M., Nicolaï S.P., Hendriks E.J., et al. Supervised exercise therapy for intermittent claudication in daily practice. JVasc Surg 2009, 49(2):363-370.
95. McDermott M.M., Liu K., Guralnik J.M., et al. Home-based walking exercise intervention in peripheral artery disease: a randomized clinical trial. JAMA 2013, 310(1):57-65.
96. Gardner A.W., Parker D.E., Montgomery P.S., et al. Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: a randomized controlled trial. Circulation 2011, 123(5):491-498.
97. Collins T.C., Lunos S., Carlson T., et al. Effects of a home-based walking intervention on mobility and quality of life in people with diabetes and peripheral arterial disease: a randomized controlled trial. Diabetes Care 2011, 34(10):2174-2179.
98. Bermingham S.L., Sparrow K., Mullis R., et al. The cost-effectiveness of supervised exercise for the treatment of intermittent claudication. Eur J Vasc Endovasc Surg 2013, 46(6):707-714.
99. Simoens S. Health economic assessment: a methodological primer. Int J Environ Res Public Health 2009, 6(12):2950-2966.
100. Murphy T.P., Cutlip D.E., Regensteiner J.G., et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the Claudication: Exercise versus Endoluminal Revascularization (CLEVER) study. Circulation 2012, 125(1):130-139.
101. Frans F.A., Bipat S., Reekers J.A., et al. Systematic review of exercise training or percutaneous transluminal angioplasty for intermittent claudication. Br J Surg 2012, 99(1):16-28.
102. Mazari F.A., Khan J.A., Carradice D., et al. Economic analysis of a randomized trial of percutaneous angioplasty, supervised exercise or combined treatment for intermittent claudication due to femoropopliteal arterial disease. Br J Surg 2013, 100(9):1172-1179.
103. Mohler E.R., Hiatt W.R., Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003, 108(12):1481-1486.
104. Kinlay S., Plutzky J. Effect of lipid-lowering therapy on vasomotion and endothelial function. Curr Cardiol Rep 1999, 1(3):238-243.
105. Aung P.P., Maxwell H.G., Jepson R.G., et al. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev 2007, (4). CD000123.
106. Ahimastos A.A., Walker P.J., Askew C., et al. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA 2013, 309(5):453-460.
107. Norgren L., Hiatt W.R., Dormandy J.A., et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). JVasc Surg 2007, 45(Suppl S):S5-S67.
108. Stephens F.B., Constantin-Teodosiu D., Greenhaff P.L. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. JPhysiol 2007, 581(Pt 2):431-444.
109. Hiatt W.R., Wolfel E.E., Regensteiner J.G., et al. Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. JAppl Physiol (1985) 1992, 73(1):346-353.
110. Dutta A., Ray K., Singh V.K., et al. L-carnitine supplementation attenuates intermittent hypoxia-induced oxidative stress and delays muscle fatigue in rats. Exp Physiol 2008, 93(10):1139-1146.
111. Luo T., Li J., Li L., et al. Astudy on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. Thromb Res 2013, 132(4):427-432.
112. Delaney C.L., Spark J.I., Thomas J., et al. Asystematic review to evaluate the effectiveness of carnitine supplementation in improving walking performance among individuals with intermittent claudication. Atherosclerosis 2013, 229(1):1-9.
113. De Haro J., Acin F., Lopez-Quintana A., et al. Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease. Heart Vessels 2009, 24(5):321-328.
114. Hammer A., Steiner S. Gene therapy for therapeutic angiogenesis in peripheral arterial disease-a systematic review and meta-analysis of randomized, controlled trials. Vasa 2013, 42(5):331-339.
115. Jorenby D.E., Leischow S.J., Nides M.A., et al. Acontrolled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. NEngl J Med 1999, 340(9):685-691.
116. Nides M., Oncken C., Gonzales D., et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006, 166(15):1561-1568.
117. Jorenby D.E., Hays J.T., Rigotti N.A., et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296(1):56-63.